Invivyd (NASDAQ:IVVD) Receives “Sell (D-)” Rating from Weiss Ratings

Invivyd (NASDAQ:IVVD)‘s stock had its “sell (d-)” rating reissued by analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

IVVD has been the subject of a number of other reports. Cantor Fitzgerald began coverage on Invivyd in a research note on Monday. They issued an “overweight” rating and a $10.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of Invivyd in a research note on Wednesday, August 27th. Finally, D. Boral Capital lifted their target price on Invivyd from $1.00 to $2.00 and gave the stock a “buy” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.14.

Invivyd Stock Performance

NASDAQ:IVVD opened at $1.64 on Wednesday. The company has a market cap of $197.03 million, a PE ratio of -1.78 and a beta of 0.57. Invivyd has a 52-week low of $0.35 and a 52-week high of $2.74. The stock has a 50-day simple moving average of $1.01 and a 200 day simple moving average of $0.81.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.08). The firm had revenue of $11.79 million for the quarter, compared to the consensus estimate of $23.16 million. Invivyd had a negative return on equity of 177.89% and a negative net margin of 238.33%. On average, research analysts predict that Invivyd will post -1.64 earnings per share for the current fiscal year.

Insider Activity at Invivyd

In other Invivyd news, insider Jill Andersen sold 49,402 shares of the stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $0.57, for a total value of $28,159.14. Following the transaction, the insider owned 84,446 shares in the company, valued at approximately $48,134.22. This represents a 36.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders sold 277,654 shares of company stock worth $167,215. 25.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Two Sigma Investments LP lifted its holdings in shares of Invivyd by 125.3% in the fourth quarter. Two Sigma Investments LP now owns 367,100 shares of the company’s stock valued at $163,000 after purchasing an additional 204,188 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Invivyd in the first quarter valued at approximately $66,000. Nuveen LLC bought a new position in shares of Invivyd in the first quarter valued at approximately $65,000. AQR Capital Management LLC lifted its holdings in shares of Invivyd by 2,051.0% in the first quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock valued at $249,000 after purchasing an additional 391,617 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in shares of Invivyd in the second quarter valued at approximately $158,000. Institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.